Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625395 | 0.95 | POLB (0.44) | FDFT1POLBMEN1KMT2AGAA | |
| SCHEMBL8619968 | 0.95 | POLB (0.47) | FDFT1POLBMEN1KMT2AGAA | |
| SCHEMBL8619955 | 0.90 | FDFT1 (0.53) | FDFT1POLB | |
| SCHEMBL8624038 | 0.88 | FDFT1 (0.57) | FDFT1POLB | |
| SCHEMBL8623396 | 0.87 | FFAR1 (0.45) | FDFT1MEN1KMT2A | |
| SCHEMBL8625401 | 0.86 | POLB (0.45) | FDFT1POLBMEN1KMT2AGAA | |
| SCHEMBL8622840 | 0.85 | FDFT1 (0.48) | FDFT1 | |
| SCHEMBL8620506 | 0.85 | S1PR1 (0.50) | FDFT1 | |
| SCHEMBL8619754 | 0.84 | FDFT1 (0.50) | FDFT1 | |
| SCHEMBL8659011 | 0.84 | FDFT1 (0.56) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |